Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | CRISPR and gene editing in clinical practice

Haydar Frangoul • 10 Dec 2020
ASH 2020
General

Haydar Frangoul, MD, Sarah Cannon Blood Cancer Center, Nashville, TN, discusses the challenges of implementing CRISPR and gene editing in clinical practice. Dr Frangoul emphasizes that patients need to have longer follow-up, and the need for more patients to be enrolled on clinical trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020

Disclosures

Haydar Frangoul, MD, is a steering committee member at Vertex Pharmaceutical.

More from Haydar Frangoul

1:43
Approval of exa-cel for SCD
Haydar Frangoul • 14 Dec 2023
0:48
Improvements in HRQoL after exa-cel in patients with transfusion-dependent β-thalassemia
Haydar Frangoul • 14 Dec 2023
0:54
CLIMB THAL-111: exagamglogene autotemcel for patients with β-thalassemia
Haydar Frangoul • 14 Dec 2023
1:33
Exagamglogene autotemcel for severe sickle cell disease
Haydar Frangoul • 14 Dec 2023

Related Videos

5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
1:12
The contribution of viral infections, such as EBV, to post-transplant lymphoproliferative disease
Susan Prockop • 16 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals